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a b s t r a c t
Parenteral vaccination campaigns are integral to the elimination of canine rabies. To maximize herd
immunity in dogs, immunocontraception provided at the time of rabies vaccination should reduce fecun-
dity and dog abundance. GonaConTM has been used successfully as an immunocontraceptive in a variety
of mammals, and by inference, the dog would be an ideal candidate for testing. As an initial step in
evaluating a combination-vaccination program, we assessed the effects of GonaConTM on rabies virus
neutralizing antibody production in dogs after administration of a veterinary rabies vaccine. Eighteen
feral/free ranging dogs were included in this initial study: six were given GonaConTM only, six were given
rabies vaccination only, and six received GonaConTM and rabies vaccination. Antibody levels were eval-
uated over 82 days. The use of the immunocontraceptive GonaConTM did not affect the ability of dogs to
seroconvert in response to the rabies vaccine. Thus, GonaConTM provides a potential immunocontracep-
tive for use in combination with rabies vaccine to increase herd immunity and address dog population
over abundance to better manage rabies.
Published by Elsevier Ltd.
1. Introduction
During the last century, extensive parenteral vaccination of host
reservoir dog populations accompanied by control of free ranging
dogs has led to the elimination of canine rabies in several coun-
tries, such as Japan [1] and the United States [2]. Almost a half of a
century later, rabies continues to challenge public health systems
in developing countries, especially in Africa and Asia, where many
of the estimated 55,000 annual human rabies deaths occur. Rabies
is a neglected tropical disease [3,4] due in part to a lack of political
will brought about by an absence of accurate data on the true public
health impact of this zoonosis [5].
The threat of rabies virus transmission to humans from dogs
increases when the density of dogs exceeds the threshold density at
which canine rabies is maintained. The threshold density for canine
rabies has been estimated to be 4.5 dogs/km2 [5]. Immunocon-
traception has been proposed to reduce the density dependence
of rabies [6]. Several targets for immunocontraception are avail-
∗ Corresponding author. Tel.: +1 602 870 2081; fax: +1 602 870 2951.
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able, such as gonadotropin-releasing hormone (GnRH). Research
has suggested that by controlling GnRH, the breeding capability of
a dog could be removed [7]. Others have shown that a GnRH vaccine
reduced the breeding capability of male dogs for at least 1 year [8].
In other species tested, GonaConTM induced infertility 2–3 times
longer in females than males. Thus, we expect the same increased
induced infertility in female dogs.
The potential for interference between simultaneously admin-
istered immunocontraceptive and rabies vaccines must be
determined before field trials using this tandem vaccination strat-
egy merit consideration. In this study, we evaluated the effects
of the immunocontraceptive vaccine GonaConTM on rabies virus
neutralizing antibody (VNA) induction in dogs from a commercial
rabies vaccine.
2. Materials and methods
2.1. GonaConTM and rabies vaccine
The GonaConTM immunocontraceptive vaccine (United States
Department of Agriculture, Animal and Plant Health Inspection
Service, Wildlife Services, National Wildlife Research Center, Fort
0264-410X/$ – see front matter. Published by Elsevier Ltd.
doi:10.1016/j.vaccine.2009.09.026
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Collins, CO, USA) formulation consisted of mammalian GnRH
conjugated to a large mollusk hemocyanin protein (keyhole
limpet hemocyanin [KLH]) and emulsified with the adjuvant
in Dog-AdjuVacTM. Each 0.5-ml dose contained 500 g of
the GnRH conjugate and 85 g (one-half the standard dose)
of inactivated Mycobacterium avium. GonaConTM was stored
and shipped under refrigerated conditions in pre-loaded, 3 ml
Air-Tite luer-hub syringes (Air-Tite Products, Virginia Beach,
VA, USA).
The rabies virus vaccine was a commercially available inacti-
vated rabies virus (DEFENSOR 3, Pfizer, Inc., New York, NY, USA).
Each 1 ml container was stored under refrigerated conditions at 4 ◦C
until ready for use.
2.2. Experimental animals
Eighteen female dogs of mixed breeds were acquired from
dog round-ups conducted by the Navajo Nation Animal Control
Program during May 2008. Unclaimed dogs gathered by Animal
Control are euthanized 3 days post round-up pursuant to the Navajo
Nation Animal Control Laws (Navajo Tribal Code; Title 13, Section
1711, Impounded Animals). Female dogs over 5 months of age were
offered for this study instead of euthanasia. Breeding age female
dogs were selected based on availability.
Dogs were separated into kennels at the Navajo Nation Animal
Control Program’s Many Farms Facility, Many Farms, Arizona, USA.
Each dog was individually marked with a collar and an attached
identification tag. Animal care personnel maintained the kennels
twice per day. Dogs were fed on commercial dog food (Ol’ Roy:
Complete Nutrition Dog Food, Wal-Mart Stores, Inc., Bentonville,
AR, USA) and offered water ad libitum. All dogs were under direct
oversight by an onsite veterinarian. Dogs were randomly assigned
to each of three treatment groups.
Group 1: Six animals. All were vaccinated with 0.5 ml of
GonaConTM immunocontraceptive. The injection was adminis-
tered intramuscularly in the upper left hind leg.
Group 2: Six animals. All were vaccinated with a single 1 ml injec-
tion of DEFENSOR-3 rabies vaccine. The vaccine was administered
intramuscularly to the upper right hind leg.
Group 3: Six animals. Each animal received a single injection of
0.5 ml GonaConTM immunocontraceptive plus a 1 ml injection of
DEFENSOR-3 rabies vaccine. The immunocontraceptive injection
was administered intramuscularly to the upper left hind leg and
the rabies vaccine was administered intramuscularly to the upper
right hind leg.
2.3. Determination of anti-GnRH antibody titers
Blood was drawn from the jugular vein of each dog on a weekly
basis using a 12 ml syringe equipped with a 20-gauge needle, or
with a 6 ml CorVacTM (Kendall, Mansfield, MA, USA) serum sepa-
rator tube and a 20-gauge needle. Blood samples were stored on
blue ice in an ice chest and then centrifuged. Serum was separated
and stored in CryoTubesTM (Nalge Nunc International, Rochester,
NY, USA) at −70 ◦C until analyzed.
To evaluate the immune responses of dogs to vaccination with
GonaConTM, we used an enzyme-linked immunosorbent assay
(ELISA) to measure anti-GnRH antibody titers [8]. In brief, a 96-
well plate was prepared by adding 100 ng of BSA-GnRH antigen to
each well and then blocking with SeaBlockTM. Fifty microlitres of
serially diluted serum was used for each assay. Anti-GnRH antibody
was determined by adding rabbit anti-dog IgG to each well, wash-
ing, then adding goat anti-rabbit IgG labeled with horse-radish
peroxidase (HRP), washing, then developing a color by adding a
HRP substrate. The color was proportional to the anti-GnRH anti-
Fig. 1. Mean rabies virus neutralizing antibody titers in dogs vaccinated with
DEFENSOR-3 rabies vaccine and GonaConTM.
body titer. BSA-GnRH was added to the ELISA plate, causing only
antibodies to GnRH to be detected.
2.4. Determination of rabies VNA titers
The coded sera were thawed rapidly and heat-inactivated in a
56 ◦C water bath for 1 h. Rabies VNA titers were determined using
the Rapid Fluorescent Focus Inhibition Test (RFFIT), as previously
described [9]. In brief, the RFFIT was performed by mixing dilutions
of test serum with a constant amount of challenge virus stan-
dard (CVS) rabies virus, 50 FFD50/0.1 ml, in multi-channeled slides
(LabTek, Thermo Fisher Scientific, Rochester, NY). After allowing
the mixture to incubate in a CO2 incubator at 37 ◦C for 90 min,
mouse neuroblastoma (MNA, C1300) cells in Eagle’s Minimum
Essential Medium with 10% (heat-inactivated) fetal bovine serum
(MEM-10) were added to each serum-virus mixture. The serum-
virus-cell cultures were incubated for 20 h in a CO2 incubator at
37 ◦C. Thereafter, the cultures were taken from the incubator, the
media was removed, and the slides were washed with PBS, fixed in
acetone, and stained with an anti-rabies virus conjugate. The fixed
cell cultures were observed under a fluorescence microscope for the
presence of fluorescing cells; 20 microscopic fields (160×–200×)
were read for each dilution and compared against a reference slide
(virus control; 50 FFD50/0.1 ml), which contained 18–20 fields of
undiluted fluorescing cells. The 50% neutralization endpoint was
defined as the dilution at which 9 or less of the 20 observed fields
contained one or more infected cells. Observed titers were con-
verted into international units by comparison with the standard
positive control rabies virus immunoglobulin (IgG) at a concentra-
tion of 2 IU/ml.
2.5. Statistical methods
SAS software was used for statistical analysis [10]. The GLM pro-
cedure for repeated measures of analysis of variance and Tukey’s
studentized range were used for comparison. Statistical differences
with P < 0.05 were considered significant.
3. Results
The anti-GnRH antibody and rabies VNA titers for each group
were determined over an 82-day period (Fig. 1). Titers were ana-
lyzed at days 0, 13, 27, 61, and 82 as shown in Table 1. Group 1
was an internal control for the rabies vaccinations administered
to Groups 2 and 3. In Group 3, for those individuals that received
both vaccines, antibody responses to GnRH and rabies virus were
measured (Fig. 2).
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Table 1
Tukey’s studentized range (HSD) test.
Treatment comparison Difference between means Simultaneous 95%
Day 0
G3–G1 0.12000 −0.10731, 0.34731
G3–G2 0.12000 −0.10731, 0.34731
G1–G3 −0.12000 −0.34731, 0.10731
G1–G2 0.00000 −0.21673, 0.21673
G2–G3 −0.12000 −0.34731, 0.10731
G2–G1 0.00000 −0.21673, 0.21673
Day 13
G2–G3 0.10800 −0.09658, 0.31258
G2–G1 0.60000 −0.40494, 0.79506***
G3–G2 −0.10800 −0.31258, 0.09658
G3–G1 0.49200 0.28742, 0.69658***
G1–G2 −0.60000 −0.79506, 0.40494***
G1–G3 −0.49200 −0.69658, −0.28742
Day 27
G2–G3 0.0000 0.0000, 0.0000
G2–G1 0.6000 0.6000, 0.6000***
G3–G2 0.0000 0.0000, 0.0000
G3–G1 0.6000 0.6000, 0.6000***
G1–G2 −0.6000 −0.6000, −0.6000***
G1–G3 −0.6000 −0.6000, −0.6000***
Day 61
G2–G3 0.0000 0.0000, 0.0000
G2–G1 0.5700 0.5700, 0.5700***
G3–G2 0.0000 0.0000, 0.0000
G3–G1 0.5700 0.5700, 0.5700***
G1–G2 −0.5700 −0.5700, −0.5700***
G1–G3 −0.5700 −0.5700, −0.5700***
Day 82
G2–G3 0.0000 0.0000, 0.0000
G2–G1 0.5700 0.5700, 0.5700***
G3–G2 0.0000 0.0000, 0.0000
G3–G1 0.5700 0.5700, 0.5700***
G1–G2 −0.5700 −0.5700, −0.5700***
G1–G3 −0.5700 −0.5700, −0.5700***
*** Comparisons significant at the 0.05 level.
There was a significant interaction between time step (F = 56.59,
P < 0.0001) and group (F = 16.28, P < 0.0001). This interaction was a
function of the negative rabies VNA titers for all individuals at time-
step-day 0 and the subsequent rise in titers for Groups 2 and 3 post
time-step-day 0.
At time-step-day 0, there was no difference in mean rabies
titers by group. For time-steps 1–4 (days 13, 27, 61, and 82) there
were statistically significant differences for the same treatment
Fig. 2. Post GnRH antibody titers following GonaConTM and rabies vaccination in
dogs.
group comparisons (between Group 3, Group 1 and Group 2). For
time-steps 1–4 (days 13, 27, 61, and 82), there was no statistically
significant difference (i.e., no evidence of interference) in mean
rabies VNA titers for the Group 2 (rabies only) and the Group 3
(rabies + GonaConTM) comparison.
4. Discussion
To our knowledge, this is the first use of the immunocontra-
ceptive GonaConTM in female dogs. We have demonstrated the
potential to use this immunocontraceptive in breeding age female
dogs without affecting parenteral rabies immunization in 100% of
vaccinated animals.
Throughout the world, there is a critical need to control popula-
tion growth in dogs, especially in areas where canine rabies remains
endemic. The current practice of euthanizing large numbers of
dogs is a social concern [11], plus it is labor intensive limiting its
potential across broad geographic areas. Alternatives to euthanasia
have focused on chemical and surgical sterilization [12,13], each
possessing positive and negative attributes. Currently applied dog
population control methods have been unable to affect a sufficient
sized cohort of dogs within a reasonable time frame to have an
impact on the local population.
More effective rabies control measures in dogs may be possible
through injectable immunocontraceptive products administered in
tandem with rabies vaccination programs. Ultimately, the factors
that would influence the population-level response to immuno-
contraception are the proportion of females that can be treated,
the incidence of non-responders among treated dogs, the fertil-
ity of untreated dogs, compensatory responses such as increased
reproductive rates in untreated animals and increased survival of
treated individuals, including rates of mortality, emigration and
immigration. Given that no interference was identified between
GonaConTM and a commercial rabies vaccine in this immunogenic-
ity trial, future research should determine the potential effects
of immunocontraception upon duration of immunity and efficacy
against relevant challenge viruses.
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